Room to Run, the Race for a COVID-19 Antibody Drug, and the Most Underappreciated Risk

<p>Another rally on Wall Street and two strategists both say there’s more room to run…where they’re finding opportunities.</p><p>The CEO of AbCellera joins to discuss the company’s partnership with Eli Lilly in the race for a COVID-19 antibody drug.</p><p>And two policy strategists weigh in one of the biggest and most underappreciated risks for the market right now.</p><p>Plus, a ‘cool’ trade for the summer.</p>